◎ Sugi Atlas

Atlas / Disease / Intracerebral hemorrhage

Intracerebral hemorrhage

disease
On this page

Also known as stroke, hemorrhagic

Summary

Intracerebral hemorrhage (MONDO:0013792) is a disease with 5 cohort genes (41 GWAS associations across 29 studies) and 277 clinical trials. Top therapeutic interventions include deferoxamine, enalapril, and eptacog alfa (activated).

At a glance

  • Cohort genes: 5
  • GWAS associations: 41
  • Clinical trials: 277

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameintracerebral hemorrhage
Mondo IDMONDO:0013792
EFOEFO:0005669
MeSHD002543
ICD-11873092535
SNOMED CT274100004
UMLSC2937358
MedGen423648
Is cancer (heuristic)no

Also known as: stroke, hemorrhagic

Data availability: 41 GWAS associations (29 studies) · 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › cerebrovascular disorder › stroke disorder › hemorrhagic stroke › intracerebral hemorrhage

Related subtypes (1): subarachnoid hemorrhage

Genetics & variants

GWAS landscape

41 GWAS associations across 29 studies. Top hits map to 14 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs5760311263e-11XKR4C3.02
chr15:785966277e-11?6.09
chr19:548538331e-10?6.17
rs29846132e-10PMF1-BGLAP, PMF1C1.33
chr1:35798933e-10?3.85
chr10:933518171e-09?5.77
chr11:625261641e-09?4.53
rs1854387952e-09CYP4F8 - CYP4F3?
chr9:1163527922e-09?2.8
chr5:988963702e-09?4.47
rs116551603e-09TMEM220-AS1 - RN7SL601PG0.82
rs342902703e-09RTN4RL1 - DPH1T0.18
rs2016801454e-09NOTCH3?3.39
rs2006466585e-09ADGRG1C1.83
chr9:187533625e-09?4.5
chr7:1009912667e-09?4.69
chr11:18875548e-09?4.67
chr14:210824209e-09?3.31
chr4:32331779e-09?3.49
chr2:1009748501e-08?3.76
rs1161613672e-08DAB1A0.45
chr13:520240542e-08?3.85
chr14:583652242e-08?4.2
chr16:30138682e-08?4.57
chr17:40541042e-08?5.45
chr10:600868212e-08?5.15
chr11:703765363e-08?4.96
chr16:26979933e-08?4.3
chr20:435749493e-08?4.48
chr7:1288461503e-08?5.33

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90246096Walters RG20236,66374,585Genotyping and population characteristics of the China Kadoorie Biobank.
GCST90473584UK Biobank Whole-Genome Sequencing Consortium20252,407456,033Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90018870Sakaue S20211,935471,578A cross-population atlas of genetic associations for 220 human phenotypes.
GCST008875Chung J20191,8081,711Genome-wide association study of cerebral small vessel disease reveals established and novel loci.
GCST008878Chung J20191,8081,711Genome-wide association study of cerebral small vessel disease reveals established and novel loci.
GCST90651323Liu TY20251,558215,981Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90137438Hu Y20211,55121,821Whole-Genome Sequencing Association Analyses of Stroke and Its Subtypes in Ancestrally Diverse Populations From Trans-Omics for Precision Medicine Project.
GCST90432122Rodriguez-Flores JL20241,53326,602NOTCH3 p.Arg1231Cys is markedly enriched in South Asians and associated with stroke.
GCST90018650Sakaue S20211,456152,022A cross-population atlas of genetic associations for 220 human phenotypes.
GCST90477978Verma A20241,441448,687Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding2
Tier 2: splice/UTR1
Tier 3: regulatory0
Tier 4: intronic/intergenic34

MAF distribution

BucketVariants
common (>=0.05)9
low_freq (0.01-0.05)1
rare (<0.01)1
unknown26

Functional consequences

ConsequenceCount
unknown22
intron_variant7
intergenic_variant4
missense_variant2
non_coding_transcript_exon_variant1
splice_region_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs576031126855373413C>A,T0.001intron_variantXKR43e-11Tier 4: intronic/intergenic
chr15:785966277e-11Tier 4: intronic/intergenic
chr19:548538331e-10Tier 4: intronic/intergenic
rs29846131156227589C>G,T0.32intron_variantPMF1-BGLAP, PMF12e-10Tier 4: intronic/intergenic
chr1:35798933e-10Tier 4: intronic/intergenic
chr10:933518171e-09Tier 4: intronic/intergenic
chr11:625261641e-09Tier 4: intronic/intergenic
rs1854387951915637050A>Gintergenic_variantCYP4F8 - CYP4F32e-09Tier 4: intronic/intergenic
chr9:1163527922e-09Tier 4: intronic/intergenic
chr5:988963702e-09Tier 4: intronic/intergenic
rs116551601710989753G>A0.24intergenic_variantTMEM220-AS1 - RN7SL601P3e-09Tier 4: intronic/intergenic
rs34290270172026424TA>T0.05intergenic_variantRTN4RL1 - DPH13e-09Tier 4: intronic/intergenic
rs2016801451915179052G>A,C,Tmissense_variantNOTCH34e-09Tier 1: coding
rs2006466581657644658A>C,Gintron_variantADGRG15e-09Tier 4: intronic/intergenic
chr9:187533625e-09Tier 4: intronic/intergenic
chr7:1009912667e-09Tier 4: intronic/intergenic
chr11:18875548e-09Tier 4: intronic/intergenic
chr14:210824209e-09Tier 4: intronic/intergenic
chr4:32331779e-09Tier 4: intronic/intergenic
chr2:1009748501e-08Tier 4: intronic/intergenic
rs116161367157744497C>A0.05intergenic_variantDAB12e-08Tier 4: intronic/intergenic
chr13:520240542e-08Tier 4: intronic/intergenic
chr14:583652242e-08Tier 4: intronic/intergenic
chr16:30138682e-08Tier 4: intronic/intergenic
chr17:40541042e-08Tier 4: intronic/intergenic
chr10:600868212e-08Tier 4: intronic/intergenic
chr11:703765363e-08Tier 4: intronic/intergenic
chr16:26979933e-08Tier 4: intronic/intergenic
chr20:435749493e-08Tier 4: intronic/intergenic
chr7:1288461503e-08Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 6 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
ACELimitedUnknownintracerebral hemorrhage6

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
ACEOrphanet:97369Renal tubular dysgenesis of genetic origin

Cohort genes → proteins

5 cohort genes, 5 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only4
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
ACEHGNC:2707ENSG00000159640P12821Angiotensin-converting enzymegencc
OR52E4HGNC:15213ENSG00000180974Q8NGH9Olfactory receptor 52E4gwas
SLC25A44HGNC:29036ENSG00000160785Q96H78Solute carrier family 25 member 44gwas
FHIP1AHGNC:34237ENSG00000164142Q05DH4FHF complex subunit HOOK-interacting protein 1Agwas
PMF1HGNC:9112ENSG00000160783Q6P1K2Polyamine-modulated factor 1gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
ACEAngiotensin-converting enzymeDipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of circulating hormones, such as angiotensin I, bradykinin or enkephalins, thereby playing a key role in the regulation of blood pressure, electrolyte hom…
OR52E4Olfactory receptor 52E4Odorant receptor.
SLC25A44Solute carrier family 25 member 44Mitochondrial solute transporter which transports branched-chain amino acid (BCAA; valine, leucine and isoleucine) into mitochondria in brown adipose tissue (BAT).
FHIP1AFHF complex subunit HOOK-interacting protein 1AProbable component of the FTS/Hook/FHIP complex (FHF complex).
PMF1Polyamine-modulated factor 1Part of the MIS12 complex which is required for normal chromosome alignment and segregation and kinetochore formation during mitosis.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.4

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Protease17.3×0.288
GPCR14.8×0.288
Other/Unknown31.1×0.608

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
ACEProteaseyes3.4.15.1Peptidase_M2
OR52E4GPCRyesGPCR_Rhodpsn, Olfact_rcpt, GPCR_Rhodpsn_7TM
SLC25A44Other/UnknownnoMCP, MCP_transmembrane, MCP_dom_sf
FHIP1AOther/UnknownnoFHIP, FHIP_KELAA_motif, FHIP_C
PMF1Other/UnknownnoPMF1/Nnf1

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)1
moderate (6-20)0
broad (>20)4
unknown0

Top tissues across cohort

TissueCohort genes
hindlimb stylopod muscle2
ileal mucosa1
left testis1
right testis1
calcaneal tendon1
colonic epithelium1
male germ line stem cell (sensu Vertebrata) in testis1
blood1
prefrontal cortex1
tendon of biceps brachii1
buccal mucosa cell1
quadriceps femoris1
apex of heart1
right lobe of thyroid gland1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
ACE177ubiquitousmarkerileal mucosa, right testis, left testis
OR52E43markermale germ line stem cell (sensu Vertebrata) in testis, calcaneal tendon, colonic epithelium
SLC25A44253ubiquitousmarkerprefrontal cortex, blood, tendon of biceps brachii
FHIP1A216broadmarkerbuccal mucosa cell, hindlimb stylopod muscle, quadriceps femoris
PMF1278ubiquitousmarkerhindlimb stylopod muscle, apex of heart, right lobe of thyroid gland

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

SymbolInteractor count
ACE3,659
PMF11,081
FHIP1A730
SLC25A44703
OR52E4254

Intra-cohort edges

ABSources
PMF1SLC25A44string_interaction

Structural data

PDB: 2 · AlphaFold-only: 3 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
ACEP1282197
PMF1Q6P1K24

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
OR52E4Q8NGH988.88
SLC25A44Q96H7880.66
FHIP1AQ05DH465.15

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 13. Enrichment computed across 5 evidence-associated genes (4 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Metabolism of Angiotensinogen to Angiotensins1158.6×0.054ACE
Branched-chain amino acid catabolism1119.0×0.054SLC25A44
Peptide hormone metabolism168.0×0.063ACE
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal129.1×0.084PMF1
EML4 and NUDC in mitotic spindle formation123.2×0.084PMF1
Resolution of Sister Chromatid Cohesion121.6×0.084PMF1
RHO GTPases Activate Formins119.4×0.084PMF1
Mitotic Prometaphase117.3×0.084PMF1
Metabolism of amino acids and derivatives116.9×0.084SLC25A44
Separation of Sister Chromatids115.2×0.084PMF1
Expression and translocation of olfactory receptors17.0×0.159OR52E4
Metabolism of proteins13.1×0.302ACE
Metabolism12.9×0.302SLC25A44

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
branched-chain amino acid transport14213.0×0.003SLC25A44
mononuclear cell proliferation14213.0×0.003ACE
regulation of renal output by angiotensin12106.5×0.003ACE
regulation of angiotensin metabolic process12106.5×0.003ACE
cell proliferation in bone marrow12106.5×0.003ACE
regulation of cold-induced thermogenesis12106.5×0.003SLC25A44
negative regulation of gap junction assembly12106.5×0.003ACE
substance P catabolic process11404.3×0.003ACE
regulation of hematopoietic stem cell proliferation11404.3×0.003ACE
antigen processing and presentation of peptide antigen via MHC class I1842.6×0.005ACE
regulation of systemic arterial blood pressure by renin-angiotensin1842.6×0.005ACE
hormone catabolic process1702.2×0.005ACE
bradykinin catabolic process1601.9×0.005ACE
regulation of smooth muscle cell migration1601.9×0.005ACE
angiotensin-activated signaling pathway1383.0×0.006ACE
amyloid-beta metabolic process1383.0×0.006ACE
neutrophil mediated immunity1351.1×0.006ACE
positive regulation of systemic arterial blood pressure1351.1×0.006ACE
protein localization to perinuclear region of cytoplasm1351.1×0.006FHIP1A
angiotensin maturation1324.1×0.007ACE
branched-chain amino acid catabolic process1263.3×0.007SLC25A44
peptide catabolic process1263.3×0.007ACE
attachment of spindle microtubules to kinetochore1234.1×0.008PMF1
hormone metabolic process1221.7×0.008ACE
regulation of vasoconstriction1200.6×0.008ACE
heart contraction1191.5×0.008ACE
hematopoietic stem cell differentiation1191.5×0.008ACE
arachidonate secretion1175.5×0.009ACE
post-transcriptional regulation of gene expression1162.0×0.009ACE
blood vessel diameter maintenance1156.0×0.009ACE

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
AlteplasePhase 3 (in late-stage trials)
Eptacog Alfa (Activated)Phase 3 (in late-stage trials)
FluoxetinePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Albumin Human, Anakinra, Celecoxib, Deferoxamine, Dimethyl Fumarate, Edaravone, Enalapril, Hydralazine, Labetalol, Mirabegron, Pioglitazone, Rosuvastatin, Simvastatin, Sodium Chloride, Spironolactone, Tranexamic Acid.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 4

Druggability breadth: 1 of 5 evidence-associated genes (20%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
ACETELMISARTAN

Top cohort targets by molecule count

SymbolMoleculesMax phase
ACE314
OR52E400
SLC25A4400
FHIP1A00
PMF100

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
TELMISARTAN4ACE
MOEXIPRIL4ACE
RAMIPRIL4ACE
LISINOPRIL ANHYDROUS4ACE
SITAGLIPTIN4ACE
TRANDOLAPRIL4ACE
CAPTOPRIL4ACE
PERINDOPRIL4ACE
QUINAPRIL4ACE
LOSARTAN4ACE
FOSINOPRIL4ACE
IMIDAPRIL4ACE
ENALAPRILAT ANHYDROUS4ACE
ENALAPRIL4ACE
BENAZEPRIL4ACE
EDETIC ACID3ACE
BENAZEPRILAT2ACE
MOEXIPRILAT2ACE
QUINAPRILAT2ACE
OMAPATRILAT2ACE
RENTIAPRIL2ACE
ZOFENOPRIL2ACE
CERONAPRIL2ACE
TEPROTIDE2ACE
SAMPATRILAT2ACE
LIBENZAPRIL2ACE
PROLINE2ACE
SPIRAPRILAT2ACE
FOSINOPRILAT2ACE
IMIDAPRILAT2ACE

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
ACE304Binding:288, Functional:8, ADMET:5, Unclassified:3

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
ACE3.4.15.1peptidyl-dipeptidase A

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
ACE304

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

29 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
TELMISARTAN4ACE
MOEXIPRIL4ACE
RAMIPRIL4ACE
LISINOPRIL ANHYDROUS4ACE
SITAGLIPTIN4ACE
TRANDOLAPRIL4ACE
CAPTOPRIL4ACE
PERINDOPRIL4ACE
QUINAPRIL4ACE
LOSARTAN4ACE
FOSINOPRIL4ACE
IMIDAPRIL4ACE
ENALAPRILAT ANHYDROUS4ACE
BENAZEPRIL4ACE
EDETIC ACID3ACE
BENAZEPRILAT2ACE
MOEXIPRILAT2ACE
QUINAPRILAT2ACE
OMAPATRILAT2ACE
RENTIAPRIL2ACE
ZOFENOPRIL2ACE
CERONAPRIL2ACE
TEPROTIDE2ACE
SAMPATRILAT2ACE
LIBENZAPRIL2ACE
PROLINE2ACE
SPIRAPRILAT2ACE
FOSINOPRILAT2ACE
IMIDAPRILAT2ACE

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1ACE
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug1OR52E4
EDifficult family or no structure, no drug3SLC25A44, FHIP1A, PMF1

Undrugged target profiles

4 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
OR52E40—
SLC25A440—
FHIP1A0—
PMF10—

Clinical trials & evidence

Clinical trials

Clinical trials: 277.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified172
PHASE243
PHASE323
PHASE115
PHASE1/PHASE29
PHASE48
PHASE2/PHASE35
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05095857PHASE4RECRUITINGThe Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury
NCT06429332PHASE4RECRUITINGInternational Care Bundle Evaluation in Cerebral Hemorrhage Research
NCT06673602PHASE4RECRUITINGFufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage
NCT06899464PHASE4NOT_YET_RECRUITINGSafety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial
NCT07044232PHASE4NOT_YET_RECRUITINGNICardipine for Fast Achievement of Systolic BP Targets in ICH
NCT07609654PHASE4NOT_YET_RECRUITINGOral Anticoagulation After Stroke With Prior ICH in Subjects With AF
NCT00699465PHASE4UNKNOWNPrevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage
NCT01918722PHASE4UNKNOWNClinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy
NCT03243175PHASE3RECRUITINGAvoiding Anticoagulation After IntraCerebral Haemorrhage
NCT03496883PHASE3ACTIVE_NOT_RECRUITINGRecombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03907046PHASE3RECRUITINGAnticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03936361PHASE3RECRUITINGStatins In Intracerbral Hemorrhage
NCT05679024PHASE3RECRUITINGStroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
NCT06763055PHASE3RECRUITINGThe Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL
NCT06863558PHASE3NOT_YET_RECRUITINGReduction of Edema With a Specialized Cocktail for Ultra-early Management in Intracerebral Hemorrhage
NCT07162363PHASE2/PHASE3NOT_YET_RECRUITINGSynergistic Minimally Invasive Surgery and Deferoxamine in ICH
NCT07227246PHASE3RECRUITINGRecombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07243704PHASE3NOT_YET_RECRUITINGReducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage
NCT07338175PHASE3RECRUITINGEfficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage
NCT00127283PHASE3COMPLETEDRecombinant Factor VIIa in Acute Intracerebral Haemorrhage
NCT01041950PHASE2/PHASE3COMPLETEDA Randomised Controlled Trial of Lumbar Drainage to Treat Communicating Hydrocephalus After Severe Intraventricular Hemorrhage
NCT01176565PHASE3TERMINATEDAntihypertensive Treatment of Acute Cerebral Hemorrhage-II
NCT01221142PHASE3UNKNOWNPilot Study of Hypothermia for Intracerebral Hemorrhage in Croatia
NCT01737541PHASE3TERMINATEDFluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage
NCT01827046PHASE3COMPLETEDMinimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III
NCT02866838PHASE2/PHASE3COMPLETEDTreatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist
NCT03044184PHASE3UNKNOWNTranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial
NCT03546283PHASE3UNKNOWNNeuroprotectant for Hypertensive Intracerebral Hemorrhage
NCT03785067PHASE3TERMINATEDTriple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study
NCT03996772PHASE3COMPLETEDPREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
NCT04522102PHASE3COMPLETEDAntiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase
NCT04604587PHASE3UNKNOWNMRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA
NCT04657133PHASE3UNKNOWNRemote Ischemic Conditioning for the Treatment of Intracerebral Hemorrhage
NCT04857632PHASE2/PHASE3UNKNOWNStatin for Neuroprotection in Spontaneous Intracerebral Hemorrhage
NCT05066620PHASE3UNKNOWNChinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial
NCT05419193PHASE2/PHASE3COMPLETEDPROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)
NCT04760717PHASE2ACTIVE_NOT_RECRUITINGRegulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke
NCT05020535PHASE2ACTIVE_NOT_RECRUITINGBiomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
NCT05369351PHASE2RECRUITINGEfficacy and Safety of Mirabegron in Intracerebral Hemorrhage
NCT05434065PHASE2RECRUITINGEffects and Mechanisms of Celecoxib on Intracerebral Hemorrhage

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
DEFEROXAMINE415
ENALAPRIL46
EPTACOG ALFA (ACTIVATED)46
APIXABAN44
FINGOLIMOD44
NICARDIPINE44
BROMOCRIPTINE43
FLUOXETINE43
PROPRANOLOL43
HYDRALAZINE42
LABETALOL42
ACYCLOVIR41
ALBUMIN HUMAN41
ALTEPLASE41
AMIKACIN41
CHOLECALCIFEROL41
CLEVIDIPINE41
CONIVAPTAN41
DABIGATRAN ETEXILATE41
DAPTOMYCIN41
DIMETHYL FUMARATE41
EDARAVONE41
EDOXABAN41
ENOXAPARIN SODIUM41
ESKETAMINE41
GANCICLOVIR41
GLYBURIDE41
LEVOTHYROXINE SODIUM41
MINOCYCLINE HYDROCHLORIDE41
MIRABEGRON41

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 70

This page pulls from 70 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd11intactinterpromedgenmeshmimmondomondochildmondoparentorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot